Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|October 2, 2021
- Pharmaceutical Technology, October 2021 Issue
- Volume 45
- Issue 10
Contamination Monitoring Instruments
Particle Measuring Systems Pro Series provides a portfolio of contamination monitoring instruments. The products include portable and remote instruments for viable and non-viable airborne particle counting and environmental monitoring and data management software.
A facility monitoring system communicates with cleanroom sensors and with central software. FacilityPro processors are compatible with the FacilityPro Smart server module or with supervisory control and data acquisition systems.
The series is compliant with current good manufacturing practices and was designed with anticipated regulatory requirements in mind. This design is intended to keep the system compliant for as long as possible, eliminating the need to order new equipment as regulations change.
Articles in this issue
about 5 years ago
Automating Aseptic Manufacturingabout 5 years ago
Considering Bio/Pharma Reformulation Strategiesabout 5 years ago
Pharma Sets a Foundation for Greener API Manufacturingabout 5 years ago
Adopting Continuous Manufacturing for Solid-Dose Drug Productsabout 5 years ago
Determining Shelf Life: Reading the Stability Testing Dataabout 5 years ago
Trends Affecting Biopharmaceutical Manufacturingabout 5 years ago
European Pharmacopoeia Updates: EDQM Tackles Nitrosamine Impuritiesabout 5 years ago
Public Trust in Medicine Quality as Public Health Challenges Emergeabout 5 years ago
FDA Moves to Advance Innovative ExcipientsRelated to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5